CN102171205B - 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂 - Google Patents

促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂 Download PDF

Info

Publication number
CN102171205B
CN102171205B CN2009801386016A CN200980138601A CN102171205B CN 102171205 B CN102171205 B CN 102171205B CN 2009801386016 A CN2009801386016 A CN 2009801386016A CN 200980138601 A CN200980138601 A CN 200980138601A CN 102171205 B CN102171205 B CN 102171205B
Authority
CN
China
Prior art keywords
crf
cyclopropyl
mmol
reaction mixture
methoxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801386016A
Other languages
English (en)
Chinese (zh)
Other versions
CN102171205A (zh
Inventor
理查德·A·哈茨
维杰伊·T·阿赫加
维夫卡南达·M·弗鲁德赫拉
乔安妮·J·布朗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102171205A publication Critical patent/CN102171205A/zh
Application granted granted Critical
Publication of CN102171205B publication Critical patent/CN102171205B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801386016A 2008-07-31 2009-04-27 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂 Expired - Fee Related CN102171205B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8523008P 2008-07-31 2008-07-31
US61/085,230 2008-07-31
PCT/US2009/041793 WO2010014280A1 (en) 2008-07-31 2009-04-27 Pyrazinone modulator of corticotropin-releasing factor receptor activity

Publications (2)

Publication Number Publication Date
CN102171205A CN102171205A (zh) 2011-08-31
CN102171205B true CN102171205B (zh) 2013-08-07

Family

ID=40651774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801386016A Expired - Fee Related CN102171205B (zh) 2008-07-31 2009-04-27 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂

Country Status (10)

Country Link
US (2) US7932256B2 (https=)
EP (1) EP2303867B1 (https=)
JP (1) JP5396474B2 (https=)
KR (1) KR20110040870A (https=)
CN (1) CN102171205B (https=)
AR (1) AR072639A1 (https=)
AU (1) AU2009277057A1 (https=)
MX (1) MX2011000754A (https=)
TW (1) TW201008926A (https=)
WO (1) WO2010014280A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
CN104955952A (zh) 2013-01-30 2015-09-30 弗·哈夫曼-拉罗切有限公司 Lna寡核苷酸碳水化合物缀合物
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
IT201900021216A1 (it) 2019-11-14 2021-05-14 Isagro Spa Processo per la preparazione di derivati piridinici e corrispondenti piridil-formammidine
CN112552184B (zh) * 2020-12-18 2022-05-10 诚达药业股份有限公司 一种含环丙基手性胺盐酸盐的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046136A1 (en) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159980A (en) * 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
CN1231473C (zh) * 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪
RU2003136151A (ru) * 2001-06-12 2005-05-20 Ньюроджин Корпорейшн (US) 2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046136A1 (en) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators

Also Published As

Publication number Publication date
US7932256B2 (en) 2011-04-26
CN102171205A (zh) 2011-08-31
JP5396474B2 (ja) 2014-01-22
US20110166160A1 (en) 2011-07-07
AR072639A1 (es) 2010-09-08
TW201008926A (en) 2010-03-01
KR20110040870A (ko) 2011-04-20
AU2009277057A1 (en) 2010-02-04
MX2011000754A (es) 2011-02-24
EP2303867B1 (en) 2014-12-17
WO2010014280A1 (en) 2010-02-04
EP2303867A1 (en) 2011-04-06
US20100029684A1 (en) 2010-02-04
US8372847B2 (en) 2013-02-12
JP2011529886A (ja) 2011-12-15

Similar Documents

Publication Publication Date Title
CN102171205B (zh) 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂
JP5439169B2 (ja) 三置換１，２，４−トリアゾール
KR102531689B1 (ko) ６，７―디히드로피라졸로［１，５―α］피라진―４（５Ｈ）―온 화합물 및 ＭＧＬＵＲ２ 수용체의 음성 알로스테릭 조절제로서의 그 용도
JP4187652B2 (ja) ニューロペプチドｙアンタゴニストとしてのキノリン誘導体
MX2008010668A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
EP3174884B1 (en) 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
AU2015357167B2 (en) 6,7-dihydropyrazolo(1,5-alpha)pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JP2009527562A (ja) ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
CN110997652B (zh) 哌啶酮甲酰基肽2受体激动剂
EP3174882B1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
SK13752003A3 (en) Substituted pyrazinones, pyridines and pyrimidines as ligands of factor releasing corticotropine
TW201625581A (zh) 側氧雜環衍生物
AU2015295299B2 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JP7785291B2 (ja) ＴｒｋＢポジティブアロステリックモジュレーター
CN1443763A (zh) 制备喹喔啉二酮的中间体
TW201609718A (zh) 唑啶以及噁嗪烷衍生物
CN1930131A (zh) 2H－或3H－苯并[e]吲唑－1－基的氨基甲酸酯衍生物、其制备及其在治疗上的应用
CZ9903052A3 (cs) Chinoxalindiony, způsoby a meziprodukty pro jejich výrobu, jejich použití, farmaceutické přípravky na jejich bázi a způsoby léčení

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130807

Termination date: 20140427